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Abstract
The effect of hemodialysis on the plasma glucose profile and liraglutide level after
liraglutide injection was investigated in patients with diabetes and end-stage renal
disease (ESRD). Either 0.6 mg or 0.9 mg liraglutide was subcutaneously
administered daily to 10 Japanese type 2 diabetic patients with ESRD.
Hemodialysis was conducted on days 1 and 3. Plasma liraglutide and glucose
concentrations were measured by enzyme-linked immunosorbent assay and a
continuous glucose monitoring system, respectively. The safety profile of liraglutide
was also assessed. Hemodialysis had no effect on the pharmacokinetic parameters
of liraglutide in patients with diabetes and ESRD; the maximum plasma
concentration (Cmax), tmax, area under the concentration-time curve (AUC), and CL/f
were unaltered. Similarly, hemodialysis did not affect the mean or minimum glucose
levels, AUC, or duration of hyperglycemia (.180 mg/dL) and hypoglycemia
(,70 mg/dL) following liraglutide administration. However, significant increases in
mean amplitude of glycemic excursions (MAGE) and standard deviation (SD) as
markers of glucose fluctuation, and the maximum glucose level were observed
during hemodialysis. No adverse events, including hypoglycemia, were observed
after liraglutide injection, either off-hemodialysis (day 2) or on-hemodialysis (day 3).
Liraglutide was well tolerated in patients with type 2 diabetes and ESRD
undergoing hemodialysis. The present results suggested that hemodialysis did not
affect the pharmacokinetic profile of liraglutide or most glycemic indices, with the
exception of MAGE, SD, and the maximum glucose level. These results suggested
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that it may be possible to use liraglutide during hemodialysis for diabetes with
ESRD, without dose adjustment.
Trial Registration: UMIN Clinical Trials Registry (UMIN-CTR) UMIN000010159
Introduction
Type 2 diabetes is a major risk factor for chronic renal diseases and many affected
individuals develop diabetic nephropathy, the leading cause of end-stage renal
disease (ESRD). In Japan, approximately 95% of diabetic patients with ESRD
receive hemodialysis [1]. The therapeutic options for diabetic patients with ESRD
requiring hemodialysis are generally limited due to the accumulation of anti-
diabetic drugs in the body by the reduction of glomerular filtration rate (GFR)
and leading to hypoglycemia [2].
The efficacy and safety of liraglutide, a long-acting glucagon-like peptide
(GLP-1) receptor agonist, have been investigated in type 2 diabetic patients [3–5].
However, evaluation of the efficacy and safety of liraglutide in non-diabetic and
diabetic patients with severe renal impairment is limited to several small studies
[6, 7]. The effect of renal impairment on the pharmacokinetics of liraglutide in 24
Caucasian patients with renal impairment was reported previously [6]. This study
evaluated the pharmacokinetics of liraglutide (0.75 mg, single-dose subcutaneous
injection) in non-diabetic patients with varying degrees of renal impairment.
Compared to healthy subjects, patients with mild, moderate, or severe renal
impairment and ESRD showed, no increase in plasma exposure of liraglutide,
indicating that the pharmacokinetics of liraglutide were not influenced by renal
function. These results in non-diabetic patients suggested that liraglutide dose
adjustment might not be required in diabetic patients with ESRD. The efficacy
and safety of low-dose liraglutide (0.3 mg) have recently been reported in nine
Japanese diabetic patients with ESRD undergoing hemodialysis, using a
continuous glucose monitoring system (CGMS) [7]. The results of this study
suggested that liraglutide had good efficacy and was well-tolerated in type 2
diabetic patients with ESRD switching from insulin therapy to liraglutide and
requiring hemodialysis. However, no previous reports have described the
measurement of plasma liraglutide concentrations in diabetic patients with ESRD
undergoing hemodialysis. Therefore, it is important to investigate whether the
liraglutide dose adjustment is required in diabetic patients requiring hemodialysis,
by evaluating its pharmacokinetic profile, efficacy and safety of liraglutide, due to
the high prevalence of renal dysfunction and limited to therapeutic options of
anti-diabetic drugs in the patients. Our primary objective was to assess the efficacy
of liraglutide in controlling blood glucose levels and to evaluate its effect on
hypoglycemia in these patients. Our secondary objective was to evaluate the effect
of hemodialysis on the plasma levels of liraglutide in type 2 diabetes patients with
ESRD.
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Materials and Methods
The protocol for this trial and supporting TREND checklist are available as
supporting information; see Checklist S1 and Protocol S1.
Ethics and Good Clinical Practice
This study was conducted in accordance with the International Conference on
Harmonisation (ICH) Good Clinical Practice (GCP) guidelines [8] and Ethical
Guidelines for Clinical Studies in Japan [9]. The investigators complied with all
applicable regulatory and legal requirements, ICH GCP guidelines, and the
Declaration of Helsinki [10] in obtaining and documenting informed consent.
Subject confidentiality was strictly maintained and no subject was involved in any
trial-related activity without obtaining appropriate written informed consent. The
study protocol was reviewed by the ethics committee at Nakakinen Clinic. Ethics
committee approval was obtained before the initiation of this study.
Patients
This single-center, open-label, pilot study was conducted in 10 diabetic patients
with type 2 diabetes and ESRD (UMIN Clinical Trial Registry 000010159) at
Nakakinen Clinic. The period of patient recruitment was between January 28,
2013 and February 28, 2013. The specific patient eligibility criteria are listed
below. Inclusion criteria: male and female patients with type 2 diabetes and ESRD;
age §20 years; treated with a stable dose of 0.6 mg or 0.9 mg liraglutide for at
least 2 weeks; glycoalbumin (GA) #30%; able to provide informed consent before
any trial-related activities. Patients were excluded if they had type 1 diabetes; had
been treated with another incretin mimetic within 3 months prior to screening;
had impaired hepatic function (measured as serum glutamic oxaloacetic
transaminase [also known as aspartate aminotransferase, AST] or serum glutamic
pyruvic transaminase [also known as alanine aminotransferase, ALT]).100 IU/L;
had unstable cardiovascular or cerebrovascular disease; were pregnant or breast-
feeding; intended to become pregnant or were female and of childbearing age and
not using adequate contraceptive methods; had known or suspected allergy to trial
medication(s), excipients, or related products; and had any contraindications to
liraglutide.
Study Design
A group of 10 patients with type 2 diabetes and ESRD requiring hemodialysis
received liraglutide (subcutaneous administration) at a dose of either 0.6 or
0.9 mg (Victoza; Novo Nordisk A/S, Denmark) from the investigators at
Nakakinen Clinic, using the Victoza pen device. The 0.9 mg dose of liraglutide is
the highest approved clinical dosage in Japan. Nine patients received 0.9 mg
liraglutide and 1 patient received 0.6 mg. Patients were admitted to hospital on
day 1 and underwent hemodialysis (hemodialyzers: NV-16U, NV-10U, and NV-
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21U [Toray Medical Co. Ltd., Chiba, Japan], FX 140 and FX 180 [Fresenius
Medical Care, Germany], APS-18SA [Asahi Kasei Medical Co. Ltd., Tokyo,
Japan]; blood flow rate of 160–220 mL/min; dialysate flow rate of 450 mL/min;
replacement flow rate of 0 mL/min; filtration flow rate of 1.3–3 L/h). On day 2,
the patients with CGMS received a dose of liraglutide at 06:00 hours and blood
samples (2 mL) were collected at the following time points: 06:00 hours (pre-
dose), 08:00, 12:00, 15:00, 18:00, 21:00, and 06:00 (day 3). These time points
equated to 0, 2, 6, 9, 12, 15, and 24 h post-dose. Hemodialysis was not conducted
in these patients on day 2. On day 3, patients with CGMS received a further dose
of liraglutide at 06:00 hours and blood samples were collected at the same time
points as on day 2. In addition, patients underwent hemodialysis between 08:00
and 12:00 hours and an additional arterial blood sample (2 mL) was collected at
the end of the hemodialysis session. On day 4, blood samples were collected at
06:00 hours (as 24 hour-samples on day 3).
Efficacy Assessments
Plasma liraglutide concentrations were measured by a validated liraglutide-
specific enzyme-linked immunosorbent assay (ELISA) method at Huntingdon
Life Sciences (Cambridgeshire, UK). Pharmacokinetic parameters were calculated
from the plasma liraglutide concentrations at each sampling point off-
hemodialysis (day 2) and on-hemodialysis (day 3) using the WinNonlin software.
The area under the concentration-time curve (AUC0-t), maximum plasma
concentration (Cmax), tmax, CL/f, and Cdialysate were calculated.
Plasma glucose concentration was measured using CGM System-Gold
(Medtronic MiniMed, Northridge, CA, USA) since CGM is useful for evaluation
of the effect of liraglutide on glucose level fluctuation in diabetic patients [11].
CGM was performed both off-hemodialysis (day 2) and on-hemodialysis (day 3).
The maximum and minimum glucose levels, average of 24-h glucose levels,
standard deviation (SD), and mean amplitude of glycemic excursions (MAGE) of
24-h glucose, AUC, and the duration of hyperglycemia (.180 mg/dL) and
hypoglycemia (,70 mg/dL) on-hemodialysis (day 3) and off-hemodialysis (day
2) were compared using SAS version 9.3 and Microsoft Excel 2003.
Safety Assessments
The severity and causal relationship to liraglutide of all treatment-related adverse
events in these patients were assessed by the investigators. A physical examination,
including vital signs (blood pressure and heart rate) and clinical laboratory
biochemical tests, was also performed on each patient.
Statistical Methods
Analyses of the plasma pharmacokinetic and glucose profiles were performed at
Huntingdon Life Sciences and the New Drug Research Center, Inc. (Tokyo,
Japan), respectively.
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The mean, maximum, and minimum glucose concentrations; SD; and MAGE
were analyzed using a paired t-test and 95% confidence interval (CI) for the mean
ratio (on-hemodialysis/off-hemodialysis). Because these values could be loga-
rithmically transformed, the transformed data were used for analyses. Some values
for duration and AUC of hyperglycemia (.180 mg/dL) and hypoglycemia
(,70 mg/dL) could not be transformed logarithmically because zero values were
included. In these cases, the original non-transformed values were analyzed by
paired t-test. Similarly, the plasma glucose and pharmacokinetic parameters
(Cmax, AUC0-t, and CL/f) were analyzed using 95% CI for the mean on-
hemodialysis/off-hemodialysis ratio. Values of p,0.05 were considered signifi-
cant.
Results
Patient Demographics and Baseline Characteristics
All 10 patients completed the study, and these patients were included in the
pharmacodynamic and pharmacokinetic evaluations (Fig. 1). The baseline
demographics and characteristics of all of these Japanese patients are shown in
Table 1.
Participants included 9 male patients and 1 female patient with an age of
65.8¡9.3 (mean¡ SD) years, body weight of 57.9¡9.8 kg, and body mass index
(BMI) of 21.4¡2.6 kg/m2. The duration of diabetes was 20.1¡9.0 years. The
baseline HbA1c and GA were 5.9¡0.9% and 21.0¡2.8%, respectively. The
diabetic patients with ESRD in this trial had high levels of creatinine
(11.4¡2.5 mg/dL) and blood urea nitrogen (BUN, 62.4¡16.9 mg/dL), and a
reduced estimated GFR (eGFR, 4.2¡1.3 mL/min/1.73 m2). The total cholesterol,
triglyceride, AST, ALT and creatinine phosphokinase (CPK) values were within
Figure 1. Patient disposition.
doi:10.1371/journal.pone.0113468.g001
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their normal reference ranges, but uric acid (7.5¡0.9 mg/dL) was slightly higher
than the normal reference range. With regard to pre-treatment history, 9 patients
had received liraglutide only more than 2 years prior to the initiation of the study.
In addition, 1 patient had previously been treated with insulin only, and had
switched to liraglutide 3 months prior to initiation of the study.
Efficacy
The time-change profile of the plasma liraglutide concentration and 95% CI for
the mean ratios at each time point on-hemodialysis (day 3) and off-hemodialysis
(day 2) are shown in Table 2. The 95% CI for each sampling time included 1. The
tmax on-hemodialysis (day 3) and off-hemodialysis (day 2) was generally 10.5 or
9.5 h after liraglutide injection, respectively. Hemodialysis did not appear to have
any effect on tmax values. Pharmacokinetic parameter values (AUC0-t, Cmax, tmax,
and CL/f) and 95% CI for their mean ratios are shown in Table 3. The mean
pharmacokinetic parameter ratios (on-hemodialysis/off-hemodialysis) were gen-
Table 1. Baseline demographics and characteristics of the patients.
Characteristic Values*
Age (years) 65.8¡9.3
Body weight (kg) 57.9¡9.8
BMI (kg/m2) 21.4¡2.6
Sex male/female** 9/1
Duration of diabetes (years) 20.1¡9.0
HbA1c (%) 5.9¡0.9
GA (%) 21.0¡2.8
Creatinine (mg/dL) 11.4¡2.5
BUN (mg/dL) 62.4¡16.9
eGFR (mg/min/1.73 m2) 4.2¡1.3
Total cholesterol (mg/dL) 152.7¡38.7
Triglyceride (mg/dL) 125.5¡68.8
AST (U/L) 11.2¡4.5
ALT (U/L) 10.2¡6.0
CPK (IU/L) 74.6¡30.5
Uric acid (mg/dL) 7.5¡0.9
Pre-treatment history
Liraglutide only (n) 9
Insulin and liraglutide*** (n) 1
*Values are mean ¡ SD (n510).
**0.9 mg (8 males and 1 female), 0.6 mg (1 male).
***1 patient had previously been treated with insulin only, and had switched to liraglutide 3 months prior to
initiation of the study.
AST: Aspartate aminotransferase (SGOT).
ALT: Alanine aminotransferase (SGPT).
BUN: Blood urea nitrogen.
CPK: Creatinine phosphokinase.
doi:10.1371/journal.pone.0113468.t001
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erally close to 1 and all 95% CIs included 1, indicating that hemodialysis had little
or no effect on Cmax, AUC0-t, or CL/f after subcutaneous administration of
liraglutide. The ratio of the venous to the arterial plasma liraglutide concentra-
tions was 0.92, close to 1, indicating that arterial and venous plasma
concentrations of liraglutide at the end of the hemodialysis session were similar.
Plasma liraglutide concentrations in the pooled dialysate samples were below the
limit of quantitation (,30 pM) for all patients, indicating that little or no
liraglutide was able to cross the dialysis membrane.
The effects of hemodialysis on plasma glucose concentrations and markers of
glucose fluctuation after the administration of liraglutide are shown in Table 4. A
significant increase in SD, MAGE, and maximum glucose level was observed on-
hemodialysis, as compared with off-hemodialysis. However, hemodialysis on day
3 did not significantly affect the mean and minimum glucose levels, or the
duration and AUC of hyperglycemia and hypoglycemia, as compared with those
observed off-hemodialysis (day 2). No sign or symptom of hypoglycemia was
observed after administration of liraglutide off-hemodialysis (day 2) or on-
hemodialysis (day 3), but 2 patients showed a slight reduction in plasma glucose
level (,70 mg/dL) for a short period on both days (off-hemodialysis [day 2]: to
67 mg/dL for 10–15 min in 2 patients; on-hemodialysis [day 3]: to 61 mg/dL for
55 min in 1 patient and to 68 mg/dL for 5 min in another patient).
Table 2. Time-change profile of plasma liraglutide concentration following subcutaneous administration of liraglutide in diabetic patients with ESRD on the
days of on-hemodialysis and off-hemodialysis.
Type of Hemodialysis Off-hemodialysis (day 2) On-hemodialysis (day 3) Mean ratio
p mol (Mean¡SE) p mol (Mean¡SE) (95% Confidence interval)
2 hr 15479¡4413 19224¡5280 1.25 (0.96–1.62)
6 hr 18663¡5218 21185¡6188 1.12 (0.86–1.45)
9 hr 19568¡4930 21582¡6260 1.08 (0.83–1.40)
12 hr 19392¡5053 20483¡5289 1.06 (0.82–1.38)
15 hr 18441¡5206 20939¡6674 1.10 (0.84–1.42)
24 hr 14486¡4902 16670¡6107 1.14 (0.88–1.49)
n510.
doi:10.1371/journal.pone.0113468.t002
Table 3. Pharmacokinetic parameters of liraglutide following subcutaneous administration of liraglutide to diabetic patients with ESRD on the day of on-
hemodialysis and off-hemodialysis.
PK parameters Off-hemodialysis (day 2) On-hemodialysis (day 3) Mean ratio
Mean ¡SD Mean¡SD (95% Confidence interval)
AUC0-t (p mol) 415700¡373200 473100¡455900 1.11 (0.97–1.26)
Cmax (p mol) 20940¡16130 22620¡20590 1.02 (0.86–1.22)
tmax (hours) 9.5¡3.3 10.5¡2.5 -
CL/f (mL/min) 200¡125 188¡151 0.90 (0.79–1.03)
-: not calculated, n510.
doi:10.1371/journal.pone.0113468.t003
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Safety
No adverse events, including signs of hypoglycemia, were observed in diabetic
patients with ESRD after the administration of liraglutide off-hemodialysis (day 2)
or on-hemodialysis (day 3). No clinical changes in the physical examination or
vital signs (blood pressure and heart rate) were observed. The values of eGFR,
total cholesterol, triglyceride, AST, ALT and CPK on day 3 after admission were
very similar to those recorded before admission. However, BUN, creatinine and
uric acid levels were significantly improved because of hemodialysis in these
patients (BUN: 62.4¡16.9 to 26.5¡8.3 mg/dL [p,0.01]; creatinine: 11.4¡2.5 to
5.9¡1.4 mg/dL [p,0.01]; uric acid: 7.5¡0.9 to 3.1¡0.7 mg/dL [p,0.01]).
Discussion
This single-center, open-label, pilot study was conducted in 10 Japanese patients
with type 2 diabetes and ESRD requiring hemodialysis in order to investigate the
effect of hemodialysis on the plasma glucose profile, plasma levels of liraglutide,
and safety following subcutaneous administration of liraglutide. The present
results suggested the possibility that a dose adjustment of liraglutide is not
required in diabetic patients with ESRD requiring hemodialysis because
hemodialysis did not affect the plasma glucose profile (mean and minimum
glucose levels, or duration and AUC of hyperglycemia and hypoglycemia), the
pharmacokinetics, or the safety of liraglutide. It has already been reported that
MAGE and SD were significantly higher on-hemodialysis than off-hemodialysis in
type 2 diabetic patients treated with insulin therapy [12]. The present study also
Table 4. Plasma glucose profiles after subcutaneous administration of liraglutide in diabetic patients with ESRD on-hemodialysis and off-hemodialysis.
Measurement items
Off-hemodialysis
(day 2)
On-hemodialysis
(day 3)
Mean ratio
(95% Confidence interval)
t-test
p values
Mean glucose level (mg/dL) 133.0¡36.5 138.7¡35.3 1.05 (0.98–1.12) 0.158
Maximum glucose level (mg/dL) 188.4¡62.4 226.2¡100.9 1.16 (1.02–1.32) 0.026**
Minimum glucose level (mg/dL) 92.7¡27.1 88.4¡21.4 0.96 (0.82–1.13) 0.596
SD (mg/dL) 22.1¡12.4 30.5¡20.1 1.32 (1.04–1.67) 0.028**
MAGE (mg/dL) 55.6¡27.4 90.0¡65.7 1.44 (1.05–1.98) 0.027**
Time (min) during 24 hr in
hyperglycemia (.180 mg/dL)
214.5¡388.4 210.0¡282.9 0.928
AUC (mg/dLNmin) during 24 hr in
hyperglycemia (.180 mg/dL)
7746.0¡17246.4 11427.5¡19184.4 0.127
Time (min) during 24 hr in
hypoglycemia (,70 mg/dL)
2.5¡5.4 6.0¡17.3 0.575
AUC (mg/dLNmin) during 24 hr in
hypoglycemia (,70 mg/dL)
5.0¡10.5 36.5¡112.0 0.406
Mean ¡ SD, n510.
*The analysis of 95% CI (log [CI]) could not be performed because zero values were included.
**p,0.05.
doi:10.1371/journal.pone.0113468.t004
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found increases in SD and MAGE, with significant differences between on-
hemodialysis and off-hemodialysis.
The therapeutic anti-diabetic drug options are limited for diabetic patients with
ESRD requiring dialysis because the associated reduction in GFR causes
accumulation of unchanged drugs and active metabolites [2], leading to the
induction of hypoglycemia. Therefore, conventional anti-diabetic drugs such as
sulfonylureas are not suitable because of the risk of prolonged hypoglycemia in
these patients [13]; recently approved DPP-4 inhibitors are used (with an
appropriate dose reduction) in diabetes patients with severe renal impairment
[14]. A GLP-1 receptor agonist, exenatide, is not recommended for use in patients
with ESRD because its AUC0–‘ and Cmax after in non-diabetic patients with ESRD
were 3.37 and 1.38 times higher than those observed in healthy controls,
respectively [15].
Insulin treatment remains the main therapy for the control of hyperglycemia in
diabetic patients with ESRD requiring hemodialysis, but it sometimes induces
severe hypoglycemia. Liraglutide binds plasma proteins, preventing rapid
elimination from the circulation [16], and is therefore considered suitable for
diabetic patients with ESRD in which GFR is reduced due to renal impairment. In
the present study, since there were no significant differences in pharmacokinetic
parameters calculated on-hemodialysis and off-hemodialysis after subcutaneous
administration of liraglutide, hemodialysis was not found to affect the
pharmacokinetics of liraglutide in these patients. The reason why the liraglutide
concentration was not affected by hemodialysis was unclear. It is possible that the
high level of liraglutide binding to albumin and a-acidic glycoprotein
(approximately 99%) prevented liraglutide from passing through the dialysis
membrane, resulting in no decrease in plasma liraglutide levels during
hemodialysis.
In addition, different degrees of renal dysfunction were not found to increase
exposure of liraglutide in a previous clinical pharmacology study [6]. Taken
together with the findings of the present study, this indicated that liraglutide dose
adjustment was not required in patients (diabetic or non-diabetic) with renal
impairment. However, there is extremely limited experience with liraglutide in
diabetic patients with ESRD undergoing hemodialysis and careful monitoring
after liraglutide administration to these patients is therefore required.
The efficacy and safety of liraglutide (at a low dose of 0.3 mg) in diabetic
patients with ESRD undergoing hemodialysis was recently reported by Terawaki
et al. [7]. In that study, the mean period of hypoglycemia after liraglutide
administration was approximately 50 min/day and a higher frequency of
hypoglycemia was observed after liraglutide injection than after administration of
insulin or DPP-4 inhibitors such as vildagliptin and alogliptin.
In the present study, no signs or symptoms of hypoglycemia were observed in
diabetic patients with ESRD off-hemodialysis (day 2) or on-hemodialysis (day 3)
after the administration of higher liraglutide doses of 0.6 mg (n51) and 0.9 mg
(n59). However, when hypoglycemia was defined as a glucose level ,70 mg/dL
in the present study, the duration of hypoglycemia in 2 patients during the off-
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hemodialysis period was 10–15 min, when their glucose levels were mildly
reduced (to 67 mg/dL), whereas the duration of hypoglycemia in 2 patients on-
hemodialysis was 55 min in 1 patient (61 mg/dL) and 5 min in another patient
(68 mg/dL). One study reported that liraglutide did not cause hypoglycemia
because it stimulated insulin secretion in a glucose-dependent manner [17], which
may explain why the frequency of hypoglycemia after liraglutide injection in
diabetic patients with ESRD was lower than that observed using insulin products,
which easily induce hypoglycemia in diabetic patients with renal impairment.
However, studies with larger sample sizes and longer treatment periods are
required to further investigate the level of hypoglycemia after liraglutide
administration in diabetic patients with ESRD requiring hemodialysis. In
addition, hemodialysis did not affect the AUC or duration of hyperglycemia
(.180 mg/dL) in the present study.
No adverse events were observed in 10 diabetic Japanese patients with ESRD
after the administration of liraglutide (0.6 mg/day or 0.9 mg/day) during the off-
hemodialysis or on-hemodialysis days in the present study. A previous study of
liraglutide (0.3 mg/day) in nine diabetic Japanese patients with ESRD also
reported no adverse events [7]. A separate study reported some adverse events (2
events of vomiting and 1 event of nausea) after a single injection of liraglutide
(0.75 mg) in non-diabetic Caucasian patients with varying degrees of renal
impairment [6]; the degree of renal impairment of the patients in this study was
not associated with an increased risk of adverse events. Vomiting and nausea are
the most common adverse events observed when first starting liraglutide injection
in diabetic patients, but these tend to decrease with continued liraglutide
treatment [18]. It is likely that the present study observed no vomiting or nausea
because the patients had been treated with a stable dose of 0.6 mg or 0.9 mg
liraglutide for at least 2 weeks before the trial commenced. The safety results of the
present and previous studies suggested that liraglutide was well tolerated and
could be used without dose adjustment during hemodialysis in diabetic patients
with ESRD.
Conclusions
Liraglutide was well-tolerated in patients with diabetes and ESRD undergoing
hemodialysis and off-hemodialysis. Hemodialysis did not increase the risk for
adverse clinical effects or altered pharmacokinetic profiles after liraglutide
injection in these patients. Therefore, these results suggested that liraglutide may
be used without dose adjustment during hemodialysis in patients with diabetes
and ESRD.
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